Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pravastatin Is Beneficial for Postmenopausal Hyperlipidemia: Seminar
March 18, 2002
- Korosho's PAL Amendment Bill Approved by LDP
March 18, 2002
- Evidence-Based Infection Control GL Established
March 18, 2002
- Sales of Bonalon Remain at 60% of Target
March 18, 2002
- ICH Meeting in Brussels Reported by Korosho
March 18, 2002
- Eisai Aims at Sales of \550 Bil. in FY2006: President Naito
March 18, 2002
- Reform Must Be Carried Out at Any Cost: Health Minister
March 18, 2002
- Giving Employees the Dream of Creating Major Firm: Mr Mascarenhas of Eli Lilly Japan
March 18, 2002
- Healthcare Reform Bills Approved by Government
March 18, 2002
- WORLD NEWS IN BRIEF
March 18, 2002
- BUSINESS NEWS IN BRIEF
March 18, 2002
- MEDICAL DEVICE NEWS IN BRIEF
March 18, 2002
- DIAGNOSTIC NEWS IN BRIEF
March 18, 2002
- OTC NEWS IN BRIEF
March 18, 2002
- Pharmacies Concerned about Effects of Revision of Medical Fees: Survey
March 18, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
March 18, 2002
- Importance of Training Rheumatologists Stressed: RDIC Seminar
March 18, 2002
- BULLETIN
March 11, 2002
- WEBSIITE NEWS
March 11, 2002
- Maruishi: Sales, Profits Up due to Increases in Exports
March 11, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…